Industry-leading covalent medicine pipeline

FMC-220

FMC-220 is a highly selective, covalent small molecule activator of the Y220C mutated tumor suppressor p53. It is designed to provide prolonged target residence time and persistent pharmacodynamic effects. These properties deliver tumor regression by driving cancer cell death.

FMC-220 is being evaluated for the treatment of solid tumor cancers with TP53 loss-of-function mutations. Preclinical studies have demonstrated that FMC-220 delivers unprecedented potency, selective engagement, and durable anti-tumor activity at low doses across a broad range of tumor models, including those harboring co-mutations such as those in KRAS. 

p53

p53 is often referred to as the “guardian of the genome” due to its critical role in maintaining genomic stability, but it can be altered in cancer with mutations such as Y220C. The Y220C mutation destabilizes the p53 protein, impairing its tumor-suppressive functions and contributing to cancer progression. It is estimated to occur in approximately 1-2% of all cancers, with a significant presence in solid tumors such as lung, breast, and colorectal cancers, as well as other cancer types.